UC
FDA approves AbbVie’s Skyrizi for UC treatment
June 20, 2024Medical Communications AbbVie, FDA, Gastrointestinal tract, UC, ibd
AbbVie has announced that the US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa) for the treatment of adult …
GSK sets up new CRISPR lab with UC, Berkeley
June 13, 2019Medical Communications GSK, UC, berkely, crispr, genetics, pharma
GSK has struck a $67 million deal with the University of California, Berkeley. British multinational GlaxoSmithKline will collaborate with UC, …
Takeda’s subcutaneous vedolizumab proves efficacious in Phase III trial for Ulcerative Colitis
October 22, 2018Sales and Marketing Takeda, UC, biologic, phase III, results, ulcerative colitis, vedolizumab
Japanese pharma firm Takeda has announced that the gut-selective biologic vedolizumab when taken as a subcutaneous (SC) injection, proved efficacious …
Transparent implant opens ‘window’ on the brain
September 4, 2013Medical Communications, Research and Development, Sales and Marketing UC, YSZ, brain
Researchers have developed a cranial implant that could act as a brain ‘window’, making life-changing procedures safer and easier. The …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
